Related Experiment Video

Updated: Jun 27, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K

NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025

Shaji K Kumar1, Natalie S Callander2, Kehinde Adekola3

  • 1Mayo Clinic Comprehensive Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 9, 2025
PubMed

Insights

The NCCN Guidelines for Multiple Myeloma (MM) Version 1.2025 offer updated recommendations for diagnosing and treating newly diagnosed and relapsed multiple myeloma. These insights focus on crucial changes in systemic therapy, improving patient care.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Practice Guidelines

Background:

  • Multiple Myeloma (MM) is a complex hematologic malignancy requiring updated treatment strategies.
  • The National Comprehensive Cancer Network (NCCN) Guidelines are a critical resource for MM management.
  • Version 1.2025 incorporates recent advancements in MM therapy.

Purpose of the Study:

  • To summarize key updates in the NCCN Guidelines for Multiple Myeloma (Version 1.2025).
  • To highlight changes specifically related to systemic therapy for MM.
  • To inform clinicians on the latest evidence-based recommendations for MM care.

Main Methods:

  • Review of the NCCN Guidelines for Multiple Myeloma, Version 1.2025.
  • Identification and synthesis of changes pertaining to systemic therapy.
  • Focus on recommendations for both newly diagnosed and previously treated MM patients.

Main Results:

  • The NCCN Guidelines Version 1.2025 include significant updates to systemic therapy regimens.
  • These updates address treatment approaches for various stages and lines of therapy in MM.
  • Specific changes impact the management of both newly diagnosed and relapsed/refractory MM.

Conclusions:

  • Clinicians should consult the NCCN Guidelines Version 1.2025 for current MM treatment standards.
  • Adherence to updated guidelines ensures optimal use of systemic therapies for MM patients.
  • These revisions reflect the evolving landscape of multiple myeloma treatment.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.3K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...